Interim report January - September 2009

Interim report January - September 2009

Strong cash flow thanks to a favourable growth and good profitability

•	Sales increased by 28 percent during the third quarter and amounted to        
                         SEK 65.2 (50.9) million. Sales during the first nine
months amounted to SEK 207.3 (166.1) million, an increase of 25 percent.

•	Gross income for the third quarter increased by 32 percent to SEK 46.5 (35.2)
million and the gross margin was 71 (69) percent. Gross income for the first
nine months amounted to SEK 145.7 (155.1) million, an increase of 27 percent. 

•	In the third quarter operating income (EBIT) amounted to SEK 7.2 (5.1)
million, an increase of 41 percent, corresponding to an operating margin of 11
(10) percent. Adjusted for one-time expenses affecting comparability the
operating margin was 13 (13) percent for the first nine months. These one-time
expenses are attributable to the first quarter and apply to the bid for Medicult
a/s and moving expenses, which together amount to SEK 3.9 million.

•	Operating income before research and development costs was strengthened during
the third quarter and gave a margin of 25 (26) percent. This means an increase
of 32 percent to SEK 16.6 (12.6) million. 

•	The Group's net income for the third quarter increased by 22 percent to SEK
7.3 (6.0) million, corresponding to earnings per share of SEK 0.37 (0.30). The
Group's net income for the first nine months amounted to SEK 23.3 (20.4)
million. Net income includes one-time expenses according to above and amounted
approximately to SEK 3.9 million. 

•	The cash flow from operating activities was strengthened during the third
quarter and amounted to SEK 15.3 (5.8) million. 

•	The equity/assets ratio amounted to 88 percent (84).

•	The Swemed Sense™ needle was approved for sales in Australia.

•	A new cooperation agreement was signed with Cellartis AB


October 26, 2009
Göteborg, Sweden 


Magnus Nilsson
CEO


Queries should be addressed to: 
Magnus Nilsson, CEO, phone +46 31 721 80 61
Eva Nilsagård, CFO, phone +46 31 721 80 13

________________________________________________________________________________
________________________________________________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. 
     The Fertility product area works with nutrient solutions (media),
cryopreservation products and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to evaluate and maintain organs
outside the body order to select usable organs and keeping them in optimal
condition while waiting for transplantation. The Stem Cell Cultivation product
area works with media and instruments to enable the use and handling of stem
cells for therapeutic purposes. 
     Vitrolife today has approximately 160 employees and the company's products
are sold in more than 85 markets. The company is headquartered in Gothenburg,
Sweden, and there are subsidiaries in USA, Australia, France, Italy and Japan.
Production facilities are located in Sweden and USA. 
     The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
________________________________________________________________________________
_________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com.
Website: www.vitrolife.com.

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on Monday
October 26, 2009 at 3:00 pm CET.

This is a translation of the Swedish version of the notice. When in doubt, the
Swedish wording prevails.